A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) plus Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients

被引：0
|
作者：
Vo, A. [1 ]
Choi, J. [1 ]
Cisneros, K. [1 ]
Kahwaji, J. [1 ]
Toyoda, M. [2 ]
Bongha, S. [2 ]
Ge, S. [2 ]
Peng, A. [1 ]
Villicana, R. [1 ]
Jordan, S. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Transplant Immunol Lab, Los Angeles, CA 90048 USA
来源：
TRANSPLANTATION | 2014年 / 98卷
关键词：
D O I：
10.1097/00007890-201407151-00320
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
1456
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] Results from a Phase I/II study involving an anti-IL-6R could hold promise for arthritis patients
    Nagda, Priti
    NANOMEDICINE, 2012, 7 (12) : 1797 - 1797
  • [42] SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol
    Tamura, Yuichi
    Takeyasu, Rika
    Takata, Tomohiro
    Miyazaki, Naoki
    Takemura, Ryo
    Wada, Michihiko
    Tamura, Yudai
    Abe, Kohtaro
    Shigeta, Ayako
    Taniguchi, Yu
    Adachi, Shiro
    Inami, Takumi
    Tsujino, Ichizo
    Tahara, Nobuhiro
    Kuwana, Masataka
    PULMONARY CIRCULATION, 2023, 13 (02)
  • [43] A phase I/II trial to investigate the safety and efficacy of rituxan® and intravenous garnmaglobulin (IVIG) as agents to desensitize highly-HLA sensitized dialysis patients awaiting kidney transplantation.
    Vo, Ashley A.
    Toyoda, Mieko
    Wang, Jennifer
    Lukovsky, Marina
    Peng, Alice
    Villicana, Rafael
    Dafoe, Don
    Jordan, Stanley C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 158 - 158
  • [44] A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer.
    Young, Kristina Hoot
    Gunderson, Andrew J.
    Gilchrist, Miranda
    Whiteford, Mark
    Kiely, Maria X.
    Hayman, Amanda
    O'Brien, David P.
    Ahmad, Rehan
    Manchio, Jeffrey V.
    Brosnan, Evelyn
    Vaccaro, Gina M.
    Li, Rui
    Simon, Miklos
    McCormick, Mary
    Drokin, Ashley
    Cramer, Julie
    Urba, Walter John
    Gough, Michael
    Crittenden, Marka R.
    Yamazaki, Tomoko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] TWENTY-FOUR WEEKS OF TREATMENT WITH A NOVEL ANTI-IL-6 RECEPTOR NANOBODY® (ALX-0061) RESULTED IN 84% ACR20 IMPROVEMENT AND 58% DAS28 REMISSION IN A PHASE I/II STUDY IN RA
    Holz, J. -B.
    Sargentini-Maier, L.
    De Bruyn, S.
    Gachalyi, B.
    Udvaros, I.
    Rojkovich, B.
    Bruk, S.
    Sramek, P.
    Korkosz, M.
    Krause, K.
    Schoen, P.
    D'Artois, J.
    Verschueren, K.
    Willems, W.
    De Swert, K.
    Arold, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 64 - 64
  • [46] A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
    Kurzrock, Razelle
    Voorhees, Peter M.
    Casper, Corey
    Furman, Richard R.
    Fayad, Luis
    Lonial, Sagar
    Borghaei, Hossein
    Jagannath, Sundar
    Sokol, Lubomir
    Usmani, Saad Z.
    de Velde, Helgi van
    Qin, Xiang
    Puchalski, Thomas A.
    Hall, Brett
    Reddy, Manjula
    Qi, Ming
    van Rhee, Frits
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3659 - 3670
  • [47] Phase I/II clinical trial of ALT-801, a T-cell receptor/IL-2 fusion protein, plus gemcitabine and cisplatin in urothelial cancer
    Fishman, Mayer N.
    Hadjenberg, Julio
    Kuzel, Timothy
    Mahipal, Amit
    Rosser, Charles Joel
    Landau, Danny
    Gupta, Shilpa
    Vaena, Daniel A.
    Agarwala, Sanjiv S.
    Mahoney, John Francis
    Hoffman-Censits, Jean H.
    Harris, Wayne
    Milhem, Mohammed M.
    Weber, Jeffrey S.
    Rhode, Peter
    Schutt, Tessa
    Hernandez, Liza
    Huang, Bee-Yau
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [48] Spontaneous and Allo-Antibody (Ab)-Stimulated IFNγ Production in NK Cells as Detected By Cytokine Flow Cytometry (Allo-CFC) Decreased in HLA-Sensitized Kidney Transplant Patients (HS Tx Pts) Desensitized With Tocilizumab (TCZ, Anti-IL-6R)+Intravenous Immunoglobulin (IVIG)
    Ge, S.
    Shin, B.
    Lovato, D.
    Karasyov, A.
    Jordan, S.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 895 - 895
  • [49] Spontaneous and Allo-Antibody (Ab)-Stimulated IFNγ Production in NK Cells as Detected By Cytokine Flow Cytometry (Allo-CFC) Decreased in HLA-Sensitized Kidney Transplant Patients (HS Tx Pts) Desensitized With Tocilizumab (TCZ, Anti-IL-6R)+ Intravenous Immunoglobulin (IVIG).
    Ge, S.
    Shin, B.
    Lovato, D.
    Karasyov, A.
    Jordan, S.
    Toyoda, M.
    TRANSPLANTATION, 2014, 98 : 895 - 895
  • [50] Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
    Karpouzas, George
    Takeuchi, Tsutomu
    Thorne, Carter
    Sheng, Shihong
    Li, Xiaoming
    Rao, Ravi
    Fei, Kaiyin
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345